HEART TEST LABORATORIES INC (HSCS) 0.8701 +0.09 (+11.38%)
0.8701 +0.09 (+11.38%)
US42254E1047 - Common Stock - Premarket: 1 +0.13 (+14.93%)
Correction: HeartSciences CEO to Participate in the Healthcare IT Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on January 25th
Correction: HeartSciences CEO to Participate in the Healthcare IT Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on January 25th
Southlake, Texas, Jan. 23, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline on January 20th, 2023, by HeartSciences (NASDAQ: HSCS;...
HeartSciences CEO to Participate in the Healthcare IT Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on January 25th
HeartSciences CEO to Participate in the Healthcare IT Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on January 25th
Southlake, Texas, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the...
HeartSciences Appoints David R. Wells to its Board of Directors, an Experienced Capital Markets and Finance Executive
HeartSciences Appoints David R. Wells to its Board of Directors, an Experienced Capital Markets and Finance Executive
Southlake, TX, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the...
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2023 Financial Results
Patient Enrollment Close to Completion and Continue to Target FDA De Novo Resubmission Around Current Fiscal Year End...
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2023 Financial Results
Patient Enrollment Close to Completion and Continue to Target FDA De Novo Resubmission Around Current Fiscal Year End
HeartSciences and Rutgers University Announce Multi-Year Collaboration to Develop AI-based ECG Algorithms
Southlake, Texas, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the...
HeartSciences and Rutgers University Announce Multi-Year Collaboration to Develop AI-based ECG Algorithms
HeartSciences to Present at the 2022 RHK Disruptive Growth Conference on December 5, 2022
Southlake, Texas, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the...
HeartSciences to Present at the 2022 RHK Disruptive Growth Conference on December 5, 2022
HeartSciences to Participate at the Benchmark Discovery One-on-One Investor Conference on December 1, 2022
Southlake, Texas, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the...
HeartSciences to Participate at the Benchmark Discovery One-on-One Investor Conference on December 1, 2022
HeartSciences’ MyoVista® Technology Used to Develop AI-ECG Algorithm to Identify Patients at High-Risk of Major Adverse Cardiovascular Events
Independent study demonstrates novel AI-ECG algorithm could provide a cost-effective strategy for improving cardiac risk stratification
HeartSciences’ MyoVista® Technology Used to Develop AI-ECG Algorithm to Identify Patients at High-Risk of Major Adverse Cardiovascular Events
Independent study demonstrates novel AI-ECG algorithm could provide a cost-effective strategy for improving cardiac risk stratification...
HeartSciences Granted European Patent for Proprietary Electrode and Cable Connections for Use with its AI-Based MyoVista® ECG
Patent builds on previously granted U.S. patent as well as strengthens and diversifies the IP portfolio and further protects future revenues
HeartSciences Granted European Patent for Proprietary Electrode and Cable Connections for Use with its AI-Based MyoVista® ECG
Patent builds on previously granted U.S. patent as well as strengthens and diversifies the IP portfolio and further protects future revenues...
HeartSciences Named as a Top 10 MedTech Startup 2022 by MedTech Outlook Magazine
HeartSciences Announces Major Milestone with the Issuance of CPT® Codes by the American Medical Association for ECG AI Analysis of Cardiac Dysfunction
Issuance of new reimbursement-related codes expected to accelerate the use and adoption of ECG-based cardiac dysfunction AI algorithms, including...
HeartSciences Granted U.S Patent for ECG Assessment of Heart Diastolic Function Using Artificial Intelligence
Patent continues to strengthen and expand IP portfolio...
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2023 Financial Results
Nearing Completion of Patient Recruitment in FDA Pivotal Clinical Validation Study of MyoVista® Remains on Track for MyoVista® FDA De Novo Resubmission...
HeartSciences to Participate and Showcase the MyoVista at the Inauguration Ceremony of the Center for Innovation at Rutgers Robert Wood Johnson University Hospital
Southlake, Texas, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc d.b.a HeartSciences (NASDAQ: HSCS), a medical technology company...
HeartSciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Southlake, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the...